Literature DB >> 7693477

Coordinate expression of beta 1 and beta 2 integrin "activation" epitopes during T cell responses in secondary lymphoid tissue.

L J Picker1, J R Treer, M Nguyen, L W Terstappen, N Hogg, T Yednock.   

Abstract

The monoclonal antibodies (mAb) 15/7 and 24 recognize unique activation-dependent, conformational epitopes on beta 1 and beta 2-integrins, respectively. The expression of both of these epitopes closely correlates with the ligand binding ability of their respective integrins, and thus serves as indicators of functional integrin "activation". Here, we have used six-parameter flow cytometry to examine the expression of these epitopes and conventional beta 1- and beta 2-integrin epitopes during human T cell activation in secondary lymphoid tissues in vivo, focusing particularly on the virgin to memory/effector cell transition. Fresh tonsil lymphocytes were stained with mAb against conventional or activation-dependent integrin epitopes, followed by staining with mAb against CD3, CD45RA, and CD45RO, thus allowing the determination of integrin epitope expression on virgin (CD3+) T cells (CD45RA+/RO-to+/-), memory/effector (CD45RA-/RO++) T cells, and T cells undergoing the virgin to memory/effector transition: transition region-1 (T1; CD45RA+to++/RO+); -2 (T2; CD45RA++/RO++); and -3 (T3; CD45RA+/RO++). Conventional beta 1- and beta 2-integrin epitopes progressively increase during the virgin to T3 stages of the transition in tonsil, in keeping with the generally higher levels of these adhesion molecules on memory/effector vs. virgin T cells. Expression of both the beta 1 (15/7)- and beta 2 (24)-integrin activation epitopes first appears on transitional T cells, and is maintained on a relatively constant number of cells (averaging 25-30%) throughout the T1-T3 stages. These epitopes are also noted on a subset of activated memory/effector T cells. Importantly, on both transitional and activated memory/effector T cell subsets, the expression patterns of the 15/7 and 24 epitopes vs. a variety of T cell activation antigens are identical, and the expression of these epitopes relative to each other is linearly correlated, findings strongly supporting the coordinate activation of beta 1 and beta 2 integrins during T cell activation in vivo. These results provide the first evidence of integrin activation during an in vivo immunologic response, and demonstrate the usefulness of mAb recognizing conformational epitopes and multiparameter flow cytometry in delineating the dynamic interplay of adhesion molecules during complex physiologic processes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693477     DOI: 10.1002/eji.1830231105

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Effects of I domain deletion on the function of the beta2 integrin lymphocyte function-associated antigen-1.

Authors:  B Leitinger; N Hogg
Journal:  Mol Biol Cell       Date:  2000-02       Impact factor: 4.138

2.  Regulation and function of an activation-dependent epitope of the beta 1 integrins in vascular cells after balloon injury in baboon arteries and in vitro.

Authors:  N Koyama; J Seki; S Vergel; E J Mattsson; T Yednock; N L Kovach; J M Harlan; A W Clowes
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

3.  The laminin-binding activity of the alpha 7 integrin receptor is defined by developmentally regulated splicing in the extracellular domain.

Authors:  B L Ziober; Y Chen; R H Kramer
Journal:  Mol Biol Cell       Date:  1997-09       Impact factor: 4.138

Review 4.  The adhesion cascade and anti-adhesion therapy: an overview.

Authors:  S R Sharar; R K Winn; J M Harlan
Journal:  Springer Semin Immunopathol       Date:  1995

Review 5.  Molecular analysis of the physiological and pathophysiological role of alpha 4-integrins.

Authors:  G Kilger; B Holzmann
Journal:  J Mol Med (Berl)       Date:  1995-07       Impact factor: 4.599

6.  Integrin-mediated mechanotransduction requires its dynamic interaction with specific extracellular matrix (ECM) ligands.

Authors:  S Jalali; M A del Pozo ; K Chen; H Miao; Y Li; M A Schwartz; J Y Shyy; S Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

7.  AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.

Authors:  Hiroyuki Fukase; Toshifumi Kajioka; Ichiro Oikawa; Naoki Ikeda; Hidetoshi Furuie
Journal:  Br J Clin Pharmacol       Date:  2020-01-28       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.